HKUMed leads global drug development using new ‘dual immunotherapy’ in liver-cancer patients, improving survival benefits; receives international approvals
Peer-Reviewed Publication
Updates every hour. Last Updated: 14-Sep-2025 11:11 ET (14-Sep-2025 15:11 GMT/UTC)